Kantonsspital St.Gallen

Abbvie M15-572 Phase 3 PsA mit inadäquater Response auf bDMARD

Mira Bartz Batliner, Carina Hutz, Andrea Rubbert Roth & Thomas Neumann

abstract A Phase 3, Randomized, Double-Blind, Study
Comparing Upadacitinib (ABT-494) to Placebo and to
Adalimumab in Subjects with Active Psoriatic
Arthritis Who Have a History of Inadequate
Response to at Least One Non-Biologic Disease
Modifying Anti-Rheumatic Drug (DMARD) – SELECT –
PsA 1
type of project clinical studies
status ongoing - follow up
start of project 2017
end of project 2024
responsible person Prof. Dr. Rubbert-Roth